Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 4
2014 6
2015 3
2016 2
2018 2
2019 3
2020 9
2021 6
2022 6
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial.
Caimi PF, Ai W, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Havenith K, Feingold J, He S, Qin Y, Ungar D, Zhang X, Carlo-Stella C. Caimi PF, et al. Among authors: qin y. Lancet Oncol. 2021 Jun;22(6):790-800. doi: 10.1016/S1470-2045(21)00139-X. Epub 2021 May 11. Lancet Oncol. 2021. PMID: 33989558 Clinical Trial.
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma.
Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O'Connor OA, Feingold JM, Ardeshna KM, Townsend W, Solh M, Heffner LT, Ungar D, Wang L, Boni J, Havenith K, Qin Y, Kahl BS. Hamadani M, et al. Among authors: qin y. Blood. 2021 May 13;137(19):2634-2645. doi: 10.1182/blood.2020007512. Blood. 2021. PMID: 33211842 Free PMC article. Clinical Trial.
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Among authors: qin y. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study.
Alderuccio JP, Ai WZ, Radford J, Solh M, Ardeshna KM, Lunning MA, Hess BT, Zinzani PL, Stathis A, Carlo-Stella C, Hamadani M, Kahl BS, Ungar D, Kilavuz T, Yu E, Qin Y, Caimi PF. Alderuccio JP, et al. Among authors: qin y. Blood Adv. 2022 Aug 23;6(16):4736-4739. doi: 10.1182/bloodadvances.2022007782. Blood Adv. 2022. PMID: 35790100 Free PMC article. No abstract available.
Clinical outcomes of older and younger patients treated with loncastuximab tesirine in the LOTIS-2 clinical trial.
Hamadani M, Spira A, Zhou X, Liao L, Chen L, Radford J, Ai W, Solh M, Ardeshna KM, Hess B, Caimi PF, Stathis A, Carlo-Stella C, Alderuccio JP, Kahl B, Wang Y, Qin Y, Xu ZC, Zinzani PL. Hamadani M, et al. Among authors: qin y. Blood Adv. 2024 Jan 9;8(1):93-98. doi: 10.1182/bloodadvances.2023010636. Blood Adv. 2024. PMID: 37871303 Free PMC article. No abstract available.
Comprehensive Annotation and Functional Exploration of MicroRNAs in Lettuce.
Deng Y, Qin Y, Yang P, Du J, Kuang Z, Zhao Y, Wang Y, Li D, Wei J, Guo X, Li L, Yang X. Deng Y, et al. Among authors: qin y. Front Plant Sci. 2021 Dec 24;12:781836. doi: 10.3389/fpls.2021.781836. eCollection 2021. Front Plant Sci. 2021. PMID: 35003165 Free PMC article.
44 results